<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Immunology Product Guide &#187; IMS Health</title>
	<atom:link href="http://www.immunologyproductguide.com/blog/tag/ims-health/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.immunologyproductguide.com/blog</link>
	<description>A comprehensive guide to immunology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 10:09:04 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Mylan Gets FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules</title>
		<link>http://www.immunologyproductguide.com/blog/2009/11/04/mylan-gets-fda-approval-for-generic-version-of-anticonvulsant-topamaxr-sprinkle-capsules/</link>
		<comments>http://www.immunologyproductguide.com/blog/2009/11/04/mylan-gets-fda-approval-for-generic-version-of-anticonvulsant-topamaxr-sprinkle-capsules/#comments</comments>
		<pubDate>Wed, 04 Nov 2009 14:32:46 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Allergies]]></category>
		<category><![CDATA[IMS Health]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Mylan Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Ortho McNeil's anticonvulsant Topamax® Sprinkle Capsules]]></category>
		<category><![CDATA[Topiramate Capsules]]></category>
		<category><![CDATA[U.S. Food and Drug Administration]]></category>

		<guid isPermaLink="false">http://www.immunologyproductguide.com/blog/?p=168</guid>
		<description><![CDATA[Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Topiramate Capsules (Sprinkle), 15 mg and 25 mg. Topiramate Capsules (Sprinkle) are the generic version of Ortho McNeil&#8217;s anticonvulsant Topamax® Sprinkle Capsules, 15 mg and 25 [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/11/Mylan-Inc.1.png"><img class="alignleft size-full wp-image-170" style="margin: 5px" src="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/11/Mylan-Inc.1.png" alt="Mylan Inc." width="200" height="123" /></a>Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Topiramate Capsules (Sprinkle), 15 mg and 25 mg. Topiramate Capsules (Sprinkle) are the generic version of Ortho McNeil&#8217;s anticonvulsant Topamax® Sprinkle Capsules, 15 mg and 25 mg. Currently, Mylan has 121 ANDAs pending FDA approval representing $85.7 billion in annual brand sales, according to IMS Health.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.immunologyproductguide.com/blog/2009/11/04/mylan-gets-fda-approval-for-generic-version-of-anticonvulsant-topamaxr-sprinkle-capsules/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
